Abstract
The present disclosure relates to pirfenidone (5-methyl-lphenyl-2-(lH)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.